Skip to main content

Carter Bruce L A's Form 4 filing

Enanta Pharmaceuticals Inc (ENTA) · filed Mar 22, 2022

Accession no.
0001062993-22-008344
Filed
Mar 22, 2022
Trade date
Mar 21, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $407.0K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Carter Bruce L ACIK 0001225503Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 21, 2022Common StockMOption exerciseAcquired+6,000$25.58+$153,4806,000Direct
Mar 21, 2022Common StockSSaleDisposed−2,676$66.70−$178,489.23,324Direct
Mar 21, 2022Common StockSSaleDisposed−307$67.23−$20,639.613,017Direct
Mar 21, 2022Common StockSSaleDisposed−2,210$68.66−$151,738.6807Direct
Mar 21, 2022Common StockSSaleDisposed−807$69.52−$56,102.640Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 21, 2022Common StockMOption exerciseDisposed−6,000$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)